Pravastatin improves outcome in hypercholesterolemia

Probability (in percent) of a cardiovascular event in patients with a plasma cholesterol concentration between 200 and 300 mg/dL (5.2 to 6.2 mmol/L) and two additional coronary risk factors who were treated with placebo or pravastatin. Pravastatin diminished the incidence of cardiovascular events, a benefit that was demonstrated within six months.